Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke "ACTION2"

Active, not recruiting

Phase 2 Results N/A

Summary of Purpose

The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following: measures of independence,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 28 October 2017.

18 Jul 2016 10 Mar 2016 28 Feb 2018 28 Feb 2018 1 Oct 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts